GlassScriptPhysician profile
David I Klumpar
NPI 1730283276
$5,451.50
in general payments reported to CMS, 2019-2025
28 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,485 · 2020: $1,106 · 2021: $310 · 2022: $918 · 2023: $526 · 2024: $107.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $632.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $632.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,630.93 | 2019-2024 | |
| Abbvie INC. | $596.08 | 2019-2023 | |
| Sun Pharmaceutical Industries INC. | $396.65 | 2019-2023 | Ilumya |
| Janssen Biotech, INC. | $277.32 | 2019-2023 | Tremfya |
| Almirall LLC | $270.14 | 2019-2022 | |
| Pfizer INC. | $252.18 | 2019-2022 | |
| Leo Pharma INC. | $202.89 | 2019-2023 | Adbry |
| E.R. Squibb & Sons, L.L.C. | $198.59 | 2022-2023 | Sotyktu |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $194.91 | 2019-2020 | |
| Vyne Pharmaceuticals INC. | $161.50 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $130.50 | 2020-2024 | Libtayo |
| Genzyme Corporation | $127.36 | 2019-2022 | |
| Incyte Corporation | $125.22 | 2022 | |
| Mayne Pharma Commercial LLC | $120.05 | 2019-2020 | |
| Epi Health, LLC | $119.07 | 2019-2021 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $97.34 | 2019 | |
| Janssen Scientific Affairs, LLC | $96.24 | 2019 | |
| Lilly USA, LLC | $87.27 | 2019-2022 | |
| Ucb, INC. | $80.25 | 2019-2022 | |
| Prugen, INC. Pharmaceuticals | $73.05 | 2019-2020 | |
| Galderma Laboratories, L.P. | $58.64 | 2019-2023 | Aklief |
| Arcutis Biotherapeutics, INC. | $41.62 | 2023 | |
| Strata Skin Sciences, INC. | $32.55 | 2019-2021 | |
| Biofrontera INC. | $20.37 | 2021 | |
| Sanofi-Aventis U.S. LLC | $17.92 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $16.66 | 2023 | Spevigo |
| Merck Sharp & Dohme LLC | $13.20 | 2019 | |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Klumpar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.